Tsuruo T, Tomida A
Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan.
Anticancer Drugs. 1995 Apr;6(2):213-8. doi: 10.1097/00001813-199504000-00003.
Since we found verapamil as a multidrug resistance (MDR) reversing agent in 1981, many MDR reversing compounds have been reported. This type of drug must have strong effects with little side effects. We recently found MS-209 and PSC-833 as reversing agents. These two compounds interacted directly with P-glycoprotein, and showed a good MDR reversing effect in vitro and in vivo. MRK16, an antibody against P-glycoprotein, also showed a good therapeutic effect against drug resistant human tumors. MS-209, PSC-833 and the antibody against P-glycoprotein are interesting candidates for clinical use in the future.
自1981年我们发现维拉帕米作为一种多药耐药（MDR）逆转剂以来，已报道了许多MDR逆转化合物。这类药物必须具有强效且副作用小的特点。我们最近发现MS-209和PSC-833作为逆转剂。这两种化合物直接与P-糖蛋白相互作用，并在体外和体内均显示出良好的MDR逆转作用。MRK16，一种抗P-糖蛋白抗体，也显示出对耐药性人类肿瘤的良好治疗效果。MS-209、PSC-833以及抗P-糖蛋白抗体是未来临床应用中令人感兴趣的候选药物。
